Retinal vascular permeability suppression by topical application of a novel VEGFR2/Src kinase inhibitor in mice and rabbits
J. Clin. Invest. Lea Scheppke, et al. 118:2337 doi:10.1172/JCI33361 [Go to this article.]

Figure 7
Topical administration of 0.7% TG100572 or 1.22% TG100801 inhibits blood-retinal barrier breakdown. EB-based quantification of retinal vascular permeability demonstrates that (A) single topical administration of TG100572 does not significantly inhibit VEGF-induced leak (n = 10). (B) Three topical administrations of TG100572 every 2 hours while EB circulates significantly inhibit VEGF-induced leak (n = 8). (C) Single topical application of TG100801 eliminates VEGF-induced leak (n = 14). Error bars indicate SEM. *P < 0.05; **P < 0.01.